| In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication F Touret, M Gilles, K Barral, A Nougairède, J Van Helden, E Decroly, ... Scientific reports 10 (1), 13093, 2020 | 409 | 2020 |
| Prolonged infectivity of SARS-CoV-2 in fomites B Pastorino, F Touret, M Gilles, X de Lamballerie, RN Charrel Emerging infectious diseases 26 (9), 2256, 2020 | 242 | 2020 |
| Heat inactivation of different types of SARS-CoV-2 samples: what protocols for biosafety, molecular detection and serological diagnostics? B Pastorino, F Touret, M Gilles, X de Lamballerie, RN Charrel Viruses 12 (7), 735, 2020 | 140 | 2020 |
| Evaluation of heating and chemical protocols for inactivating SARS-CoV-2 B Pastorino, F Touret, M Gilles, X de Lamballerie, RN Charrel BioRxiv, 2020.04. 11.036855, 2020 | 72 | 2020 |
| Evaluation of chemical protocols for inactivating SARS-CoV-2 infectious samples B Pastorino, F Touret, M Gilles, L Luciani, X de Lamballerie, RN Charrel Viruses 12 (6), 624, 2020 | 71 | 2020 |
| Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 F Touret, JS Driouich, M Cochin, PR Petit, M Gilles, K Barthélémy, ... Antiviral research 193, 105137, 2021 | 35 | 2021 |
| Replicative fitness of a SARS-CoV-2 20I/501Y. V1 variant from lineage B. 1.1. 7 in human reconstituted bronchial epithelium F Touret, L Luciani, C Baronti, M Cochin, JS Driouich, M Gilles, L Thirion, ... MBio 12 (4), 10.1128/mbio. 00850-21, 2021 | 32 | 2021 |
| Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B. 1.1. 7), Beta (B. 1.351) and Delta … A Weiss, F Touret, C Baronti, M Gilles, B Hoen, A Nougairède, ... PloS one 16 (12), e0260958, 2021 | 25 | 2021 |
| Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone F Touret, M Gilles, R Klitting, F Aubry, X de Lamballerie, A Nougairède Emerging Microbes & Infections 7 (1), 1-12, 2018 | 21 | 2018 |
| Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 JS Driouich, M Cochin, F Touret, PR Petit, M Gilles, G Moureau, ... EBioMedicine 82, 2022 | 9 | 2022 |
| Replicative fitness SARS-CoV-2 20I/501Y. V1 variant in a human reconstituted bronchial epithelium F Touret, L Luciani, C Baronti, M Cochin, JS Driouich, M Gilles, L Thirion, ... BioRxiv, 2021.03. 22.436427, 2021 | 4 | 2021 |
| Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B. 1.1. 7 and SA B. 1.351 variant A Weiss, F Touret, C Baronti, M Gilles, B Hoen, A Nougairède, ... bioRxiv, 2021.04. 26.441457, 2021 | 3 | 2021 |
| Long-term infectivity of Chikungunya virus stored in the Dark at 4 C L Pezzi, O Py, M Gilles, PM Saba Villarroel, I Diarra, T Fourié, EA Gould, ... Vector-Borne and Zoonotic Diseases 21 (12), 989-993, 2021 | 2 | 2021 |
| Replicative fitness SARS-CoV-2 20I/501Y. V1 variant in a human reconstituted bronchial epithelium (preprint) F Touret, L Luciani, C Baronti, M Cochin, JS Driouich, M Gilles, L Thirion, ... | | 2021 |
| Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2 (preprint) JS Driouich, M Cochin, F Touret, PR Petit, M Gilles, G Moureau, ... | | 2021 |
| In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication (preprint) F Touret, M Gilles, K Barral, A Nougairede, E Decroly, X de Lamballerie, ... | | 2020 |
| Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 (preprint) F Touret, JS Driouich, M Cochin, PR Petit, M Gilles, K Barthelemy, ... | | 2020 |
| Current status of pathogen handling in European laboratories: focus on viral inactivation process Regulations and practices for handling pathogens B Pastorino, F Touret, M Gilles, RN Charrel Frontiers in Bioengineering and Biotechnology 12, 1422553, 0 | | |
| Prolonged viability of SARS-CoV-2 in fomites B Pastorino, F Touret, M Gilles, X de Lamballerie, R Charrel OSF, 0 | | |
